LivaNova PLC (LIVN)
適正価値ファンダメンタル
64
株価
$75.44
時価総額
$4.21B
パート1 · 企業の価値
概要
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月19日 with claude-haiku-4-5 — shared with all users
Through its Maquet Cardiopulmonary unit, Getinge sells the heart-lung machines, oxygenators and ECMO circuits that LivaNova's Cardiopulmonary segment sells to the same hospital perfusion and cardiac-surgery departments worldwide.
Terumo's cardiovascular business supplies oxygenators, perfusion systems and disposables for open-heart surgery, overlapping directly with LivaNova's largest revenue line and competing for the same hospital tenders.
Medtronic competes on both of LivaNova's fronts — cardiopulmonary bypass equipment and disposables for cardiac surgery, and implantable neurostimulators used in drug-resistant epilepsy and difficult-to-treat neurological conditions.
NeuroPace's RNS responsive neurostimulation system targets the same drug-resistant focal epilepsy patients, and the same implanting epilepsy centres, that LivaNova's VNS Therapy depends on.
Haemonetics competes in the surgical blood-management products used in the same cardiac operating room, where LivaNova sells autotransfusion and blood-handling systems alongside its bypass equipment.
This privately held UK manufacturer sells perfusion monitoring and extracorporeal circuit systems to the same cardiac surgery units, and is named by LivaNova itself among its principal competitors.
貸借対照表と流動性
売上高
$1.47B
直近12か月（2026/6/30まで）
純利益
$189M
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$173M
自己資本合計
$1.20B
負債合計
$1.41B
流動比率
1.45
利払い倍率
5.43
負債/EBITDA
1.34
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$67.01
現在株価
$75.44
安全マージン
-12.6%
適正価値レンジ
$48.94 - $85.07
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
22.57
ROE
-20.2%
P/B レシオ
3.18
P/FCF
28.42
粗利益率
68.1%
ROIC
7.7%
収益性レーダー
価値創造（経済的モート）
ROIC
7.7%
WACC
9.7%
ROIC − WACC
-2.0 pp
ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。
ファンダメンタル分析基準
合格（18）
- Price CAGR 5.55%
- ROIC 7.7%
- Gross Margin 68.1%
- P/FCF 28.42
- Debt/Equity ratio
- Operating Margin 12.7%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 15.4%
- Revenue Growth 5Y 8.2%
- Analyst Consensus 81% Buy
- Earnings Surprise avg 10.3%
- Earnings Quality (OCF/NI) 1.32
- Share Dilution -0.0%
- Net Margin Trend 12.8% vs -16.1%
不合格（7）
- EPS shows upward trend
- P/B Ratio 3.18
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Piotroski F-Score 4/9
データなし（2）
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-スコア
まちまちのシグナル：一部の領域に注意が必要
利益の質
高品質：利益はキャッシュに裏付けられている
株式希薄化
株式を買い戻している。株主に友好的
機関投資家の保有
この企業について機関投資家の報告はありません。
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Vladimir A. Makatsaria | CEO & Director | 52 |
| Mr. Alex Shvartsburg C.M.A. | Chief Financial Officer | 55 |
| Ms. Natalia Sergeyevna Kozmina | Chief Human Resources Officer | 54 |
| Mr. Ahmet Tezel Ph.D. | Chief Innovation Officer | 50 |
| Ms. Lindsey Little | VP & Chief Accounting Officer | - |
| Briana Gotlin | Vice President of Investor Relations | - |
| Ms. Anne M. Liddy | Chief Legal Officer | 49 |
| Deanna Wilke | Vice President of Corporate Communications | - |
| Mr. Philip Kowalczyk | Chief Strategy & Corporate Development Officer | - |
| Mr. Paul R. Buckman | President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement | 69 |
監査リスク
9
取締役会リスク
3
報酬リスク
2
株主権利リスク
2
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for LIVN, sourced from Markets Gazette.
- 2/25/2026NEUTRALLivaNova (LIVN) Q4 2025 Earnings Call Transcript
The transcript of LivaNova PLC's Q4 2025 earnings conference call is now available, providing investors with a critical opportunity to delve into the company's financial performance and future outlook. While the specific content has not been disclosed, analysts and shareholders will be scrutinizing management's statements regarding revenues, profit margins, product pipeline, and guidance for the current fiscal year. This data is essential for assessing LivaNova's operational health and anticipating potential stock movements, thereby influencing both short-term and long-term investment strategies.
via Markets Gazette